Doosan Babcock has been awarded a £25M contract by healthcare giant GlaxoSmithKline (GSK) to create a new Active Pharmaceutical Ingredients (API) facility at the GSK Montrose site in Angus, Scotland.
The firm will work with GSK to design, build and install the three storey facility. Doosan Babcock will field a team of 40 engineers on the project. The team have completed an initial front end engineering design study in 2014.
GSK will recruit 25 employees at the facility once it is complete in summer 2016.
Doosan Babcock chief executive officer Andrew Hunt said: “This is a milestone contract for Doosan Babcock and it is great to see that our major investment and ongoing work in Scotland’s pharmaceutical sector is being noticed.
“We are proud to be working with GSK on a project that will offer a major boost to the local economy, bring jobs to the region, and ultimately provide essential healthcare products for millions of people.”
The API facility will produce active ingredients for three of GSK’s new medicines for the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease.
Elsewhere in Scotland Doosan Babcok has made a £6M investment in a new Process Engineering Centre at its Renfrew site, backed by a £1.5M grant from Scottish Enterprise.
This has already seen the creation of 25 skilled jobs and paved the way for the development of an engineering skills ‘centre of excellence’ to support customers in the pharmaceutical and process industries.
